TL;DR
Overall, TRK61 shows strong lytic activity and in vivo efficacy, supporting its potential as a therapeutic or biocontrol agent against MDR Klebsiella.
It is suggested that vB_Kp_H122 may have potential as an antibacterial candidate against K57 MDR‐hvKP isolates, a novel lytic phage that specifically targets K57 capsular‐type MDR‐hvKP.
Sequential phage-antibiotic treatment was effective against MDR-HvKp biofilms, with pre-phage exposure enhancing antibiotic access through biofilm disruption, and the bacteriostatic nature of tigecycline reduced efficacy by affecting phage replication.
It is demonstrated that the phage cocktail-amikacin combination effectively targets planktonic cells, persister cells, and biofilms, providing a promising strategy against persisters and recurrent K. pneumoniae infections.
The findings suggest that, while all three phages exhibit high environmental resilience, Phage P25 is the most promising candidate for further genomic safety validation, serving as a vital biological component in therapeutic phage cocktail formulations to manage XDR vibriosis in sustainable aquaculture.
Suggestion that in vitro evaluation of MMRP1 and MMRP4 are highly recommended to more deeper future experimental studies to combat MDR E. cloacae nosocomial infections supported by genomic foundation and eventually, the possibility to be suitable for phage-engineering applications in clinical settings is highlighted.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
